Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tiefenbacher Pharmaceuticals Prepares Launch of the Anticoagulant Rivaroxaban
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 04, 2024
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Acquired Approval for Manufacturing and Marketing Generic Drugs
Details : Rivaroxaban OD Tablets (rivaroxaban) is an oral factor Xa inhibitor, which is indicated for prevention of ischemic stroke and systemic embolism in patients with non-valvular atrial fibrillation.
Product Name : Rivaroxaban OD Tablets
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 15, 2024
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 16, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto-Generic (rivaroxaban) is a factor Xa inhibitor, anticoagulant small molecule drug. It is indicated for the treatment of deep vein thrombosis, pulmonary embolism & venous thromboembolism.
Product Name : Xarelto-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2022
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Convenient Treatment Option for Thromboembolic Events
Details : Rivaroxaban oral suspension, inhibits free FXa and prothrombinase activity. It has no direct effect on platelet aggregation, but indirectly inhibits platelet aggregation induced by thrombin. By inhibiting FXa, it decreases thrombin generation.
Product Name : Rivaroxaban-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 04, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Hematology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagu...
Product Name : Xarelto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 01, 2023
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Hematology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
New Real World Study Data on Reduced Risk of Adverse Kidney Outcomes for Xarelto™ Compared to Vka
Details : Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagu...
Product Name : Xarelto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 03, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Xarelto (rivaroxaban) is an orally bioavailable factor Xa inhibitor and does not require a cofactor (such as Anti-thrombin III) for activity. Activation of factor X to factor Xa via the intrinsic and extrinsic pathways plays a central role in blood coagu...
Product Name : Xarelto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 03, 2023
Lead Product(s) : Rivaroxaban
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rivaroxaban is the most broadly indicated non-vitamin K antagonist oral anticoagulant (NOAC) worldwide and is marketed under the brand name Xarelto. Xarelto is approved for more venous and arterial thromboembolic (VAT) conditions.
Product Name : Xarelto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 21, 2022
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Results from the extension part of the COMPASS study support the long-term use of Xarelto (rivaroxaban) plus aspirin for vascular protection in patients with chronic coronary artery disease (CAD) and/or peripheral artery disease (PAD).
Product Name : Xarelto
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 23, 2022
Lead Product(s) : Rivaroxaban,Aspirin
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable